Skip to main content
Back to Trials
NCT06832878PHASE4Recruiting

Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty

Mayo Clinic

Start Date

6/1/2026

Completion Date

6/1/2027

Summary

The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria * Adults aged \> 18 years (All women of childbearing potential undergo pregnancy testing prior to THA as per our institutional protocol) * Written informed consent * Patients undergoing primary THA diagnosis of end-stage osteoarthritis * Patients receiving spinal anesthesia * Patients being discharged on postoperative day 1 Exclusion Criteria * Patients with a TXA allergy * Patients undergoing revision procedures * Patients undergoing primary THA for a diagnosis other than end-stage osteoarthritis * Patients receiving general anesthesia * Patients being discharged on the same day of surgery * Cancer patients * Patients with a history of prior VTE event * Patients on preoperative anticoagulants other than ASA * Pregnant patients (All women of child bearing potential undergo pregnancy testing prior to THA as per our institutional protocol) * Female patients who are on hormonal contraception * Patients with history of retinal vein or artery occlusion

Interventions

DRUG

Oral Tranexamic Acid

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Arthroplasty

Locations

Mayo Clinic in Arizona

Scottsdale, Arizona 85259

United States